Edition:
United States

Zealand Pharma A/S (ZELA.CO)

ZELA.CO on Copenhagen Stock Exchange

121.50DKK
24 May 2017
Change (% chg)

kr.-5.50 (-4.33%)
Prev Close
kr.127.00
Open
kr.126.50
Day's High
kr.127.00
Day's Low
kr.121.00
Volume
151,864
Avg. Vol
137,843
52-wk High
kr.137.50
52-wk Low
kr.85.50

ZELA.CO

Chart for ZELA.CO

About

Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and... (more)

Overall

Beta: 0.87
Market Cap(Mil.): kr.3,180.12
Shares Outstanding(Mil.): 26.17
Dividend: --
Yield (%): --

Financials

  ZELA.CO Industry Sector
P/E (TTM): -- 138.86 17.42
EPS (TTM): -4.52 -- --
ROI: -23.83 2.17 -5.45
ROE: -47.49 0.04 -4.73

BRIEF-Zealand Pharma: positive Phase 2a results with microdoses of dasiglucagon

* POSITIVE PHASE 2A RESULTS WITH MICRODOSES OF DASIGLUCAGON SUPPORT USE IN A DUAL-HORMONE ARTIFICIAL PANCREAS SYSTEM

May 23 2017

BRIEF-Zealand Q1 net loss DKK 26.3 million

* REG-ZEALAND REPORTS RESULTS FOR THE FIRST THREE MONTHS OF 2017 (UNAUDITED)

May 17 2017

BRIEF-Zealand Pharma Q1 royalty revenue DKK 8.0 million

* ZEALAND REPORTS ROYALTY REVENUE OF DKK 8.0 MILLION IN Q1 2017

Apr 28 2017

BRIEF-Zealand Pharma says patient recruitment completed for Phase II trial with glepaglutide

* Patient recruitment completed for Phase II trial with glepaglutide for treatment of short bowel syndrome

Feb 06 2017

BRIEF-Zealand Pharma completes Patient recruitment for phase II trial with glepaglutide

* Patient recruitment completed for phase II trial with glepaglutide for treatment of short bowel syndrome

Feb 06 2017

More From Around the Web

Earnings vs. Estimates